Is It Time to Move Beyond GVHD-Free, Relapse-Free Survival as a Primary End Point in Hematopoiet

Journal of Clinical Oncology (JCO) published a clinical update in Oncology on 21 Jan 2026. The item focuses on Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation?. Review the original article for the full source wording and details.